Financial Snapshot

Revenue
$78.62M
TTM
Gross Margin
97.84%
TTM
Net Earnings
-$533.3M
TTM
Current Assets
$1.047B
Q3 2024
Current Liabilities
$117.2M
Q3 2024
Current Ratio
893.78%
Q3 2024
Total Assets
$1.498B
Q3 2024
Total Liabilities
$257.6M
Q3 2024
Book Value
$1.241B
Q3 2024
Cash
$168.4M
Q3 2024
P/E
-2.163
Nov 29, 2024 EST
Free Cash Flow
-$473.1M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $86.18M $1.616B $1.095B $76.37M $8.091M $10.67M $2.708M
YoY Change -94.67% 47.51% 1334.39% 843.86% -24.16% 293.94%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $86.18M $1.616B $1.095B $76.37M $8.091M $10.67M $2.708M
Cost Of Revenue $2.765M $146.3M $65.87M $0.00 $0.00
Gross Profit $83.42M $1.469B $1.030B $76.37M $8.091M
Gross Profit Margin 96.79% 90.94% 93.99% 100.0% 100.0%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $178.0M $161.8M $160.8M $70.94M $37.60M $29.13M $20.99M
YoY Change 10.07% 0.6% 126.67% 88.67% 29.07% 38.78%
% of Gross Profit 213.45% 11.01% 15.62% 92.89% 464.69%
Research & Development $589.7M $474.6M $448.0M $302.4M $148.5M $100.2M $62.51M
YoY Change 24.23% 5.95% 48.14% 103.68% 48.13% 60.34%
% of Gross Profit 706.91% 32.3% 43.51% 395.99% 1835.03%
Depreciation & Amortization $18.90M $6.300M $5.300M $4.400M $3.300M $1.600M $300.0K
YoY Change 200.0% 18.87% 20.45% 33.33% 106.25% 433.33%
% of Gross Profit 22.66% 0.43% 0.51% 5.76% 40.79%
Operating Expenses $767.7M $636.4M $608.8M $373.3M $186.1M $129.4M $84.21M
YoY Change 20.63% 4.54% 63.06% 100.65% 43.84% 53.63%
Operating Profit -$684.3M $833.1M $420.8M -$297.0M -$178.0M -$118.7M -$81.50M
YoY Change -182.14% 98.0% -241.68% 66.86% 49.95% 45.64%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $65.10M -$83.05M $138.5M $2.840M $8.510M $2.540M $640.0K
YoY Change -178.39% -159.97% 4776.34% -66.63% 235.04% 296.88%
% of Operating Profit -9.97% 32.91%
Other Income/Expense, Net $56.11M -$78.79M $129.1M $1.631M -$3.450M $2.328M $721.0K
YoY Change -171.22% -161.05% 7812.39% -147.28% -248.2% 222.88%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$628.2M $754.3M $549.8M -$298.6M -$174.5M -$116.4M -$80.78M
YoY Change -183.28% 37.19% -284.12% 71.1% 49.99% 44.06%
Income Tax -$13.08M $238.4M $21.22M $54.00K $154.0K -$480.0K -$10.92M
% Of Pretax Income 31.61% 3.86%
Net Earnings -$615.1M $515.8M $528.6M -$298.7M -$174.7M -$115.9M -$69.85M
YoY Change -219.25% -2.41% -276.98% 70.98% 50.74% 65.9%
Net Earnings / Revenue -713.76% 31.92% 48.25% -391.09% -2158.98% -1086.28% -2579.47%
Basic Earnings Per Share -$4.59 $3.89 $4.07 -$2.51 -$5.76
Diluted Earnings Per Share -$4.59 $3.83 $3.96 -$2.51 -$5.76 -$1.059M -$158.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $1.522B $2.402B $708.1M $736.9M $383.4M $98.40M $187.9M
YoY Change -36.62% 239.2% -3.9% 92.2% 289.63% -47.63%
Cash & Equivalents $241.6M $848.6M $347.8M $436.6M $109.3M $47.60M $187.9M
Short-Term Investments $1.281B $1.553B $360.3M $300.3M $274.1M $50.80M $0.00
Other Short-Term Assets $65.82M $117.0M $81.60M $35.50M $19.60M $19.40M $4.400M
YoY Change -43.76% 43.43% 129.85% 81.12% 1.03% 340.91%
Inventory
Prepaid Expenses
Receivables $0.00 $773.1M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.588B $2.519B $1.563B $772.4M $403.0M $117.8M $192.4M
YoY Change -36.95% 61.19% 102.33% 91.66% 242.11% -38.77%
Property, Plant & Equipment $167.2M $188.2M $130.1M $79.90M $16.30M $12.30M $5.100M
YoY Change -11.14% 44.68% 62.77% 390.18% 32.52% 141.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $105.3M $23.93M $201.4M $24.30M
YoY Change 339.98% -88.12%
Other Assets $18.86M $21.23M $9.781M $15.70M $15.80M $7.700M $1.300M
YoY Change -11.16% 117.01% -37.7% -0.63% 105.19% 492.31%
Total Long-Term Assets $330.8M $283.0M $391.4M $146.4M $109.1M $73.80M $59.20M
YoY Change 16.9% -27.7% 167.38% 34.19% 47.83% 24.66%
Total Assets $1.919B $2.802B $1.954B $918.8M $512.1M $191.6M $251.6M
YoY Change
Accounts Payable $6.334M $6.422M $6.521M $5.100M $5.900M $6.500M $4.900M
YoY Change -1.37% -1.52% 27.86% -13.56% -9.23% 32.65%
Accrued Expenses $104.2M $489.1M $141.5M $76.70M $26.30M $14.50M $7.500M
YoY Change -78.69% 245.62% 84.5% 191.63% 81.38% 93.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $200.0K
YoY Change 50.0%
Total Short-Term Liabilities $175.4M $511.0M $341.2M $99.10M $59.20M $39.90M $12.40M
YoY Change -65.68% 49.76% 244.34% 67.4% 48.37% 221.77%
Long-Term Debt $0.00 $0.00 $0.00 $700.0K $900.0K $0.00 $0.00
YoY Change -100.0% -22.22%
Other Long-Term Liabilities $153.4M $209.8M $162.7M $98.90M $24.70M $18.40M $12.20M
YoY Change -26.89% 28.95% 64.55% 300.4% 34.24% 50.82%
Total Long-Term Liabilities $153.4M $209.8M $162.7M $99.60M $25.60M $18.40M $12.20M
YoY Change -26.89% 28.95% 63.39% 289.06% 39.13% 50.82%
Total Liabilities $328.8M $724.1M $522.4M $201.9M $88.10M $61.60M $28.00M
YoY Change -54.59% 38.61% 158.75% 129.17% 43.02% 120.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 134.1M shares 132.6M 129.9M 119.2M 30.35M
Diluted Shares Outstanding 134.1M shares 134.8M 133.4M 119.2M 30.35M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.1534 Billion

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 587 full-time employees. The company went IPO on 2019-10-11. The firm's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The firm's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. The company also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Industry: Biological Products, (No Diagnostic Substances) Peers: ACADIA PHARMACEUTICALS INC AMICUS THERAPEUTICS, INC. ARROWHEAD PHARMACEUTICALS, INC. BIOCRYST PHARMACEUTICALS INC INSMED Inc Prometheus Biosciences, Inc. Relay Therapeutics, Inc. Sage Therapeutics, Inc. Ultragenyx Pharmaceutical Inc.